Gene Knowledge Graph
UTC
Sensitive

Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)

near HLA-DRB1 · rs2454138

Where this position leads

Condition: Multiple Sclerosis

rs2454138 Condition: Multiple Sclerosis Multiple Sclerosis Condition rs2454138 rs2454138 near HLA-DRB1

What the study found

Who was studied 926 European ancestry individuals, 7 Hispanic individuals, 1 Asian ancestry individuals, 1 African ancestry individual, 4 other unknown ancestry individuals, 2 individuals.

The effect Each copy of the A allele shifted the measure 0.41 higher (95% confidence interval 0.31-0.51); p = 5 × 10−19.

How common The A allele had a frequency of about 22% in the people studied.

Where it sits Chromosome 6, band 6p21.32 — between genes, 12.8 kb from HLA-DRB1.

What each result means

A/A Published research associates this genotype (two copies of the reported risk allele) with a higher likelihood of Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels) compared to the general population.
A/G Published research associates this genotype (one copy of the reported risk allele) with an intermediate association with Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels).
G/G Published research associates this genotype with typical/baseline likelihood of Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels) — no copies of the reported risk allele.
Source
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials
Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M
and 9 more — show all
Hartung HP, Jeffery D, Kappos L, Barkhof F, Edan G, Freedman MS, Montalbán X, Müller-Myhsok B, Hemmer B
BEYOND and BENEFIT Study Groups
Multiple sclerosis (Houndmills, Basingstoke, England) · 2019 · PMID 29521573

Questions about rs2454138

What is rs2454138?

rs2454138 is a single position in the genome, in or near the near HLA-DRB1 gene. Published research associates it with neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels). A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.

What conditions is rs2454138 linked to?

On MyGeneLog this position is linked to Multiple Sclerosis. The research behind each link, and its sources, are set out on that condition page.

Does having rs2454138 mean I will get this?

No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.

Where does the information about rs2454138 come from?

GWAS Catalog, Mult Scler 2018, PMID:29521573. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.

Quoting this page

Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.

Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels) (rs2454138). MyGeneLog™. https://www.mygenelog.com/variants/rs2454138

← See all variants